Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe - A Long-term Use Survey in Patients with Rheumatoid Arthritis -

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223691

Enrollment

1000

Registered

2017-10-25

Start date

2017-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) INN of investigational material : denosumab Therapeutic category code : 399 Agents affecting metab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients who receive PRALIA for the first time

Exclusion criteria

Exclusion criteria: Those who previously used PRALIA for osteoporosis treatment

Design outcomes

Primary

Measure	Time frame
efficacy safety 1.Safety - Incidence by adverse drug reactions/infection type - Incidence of serious adverse events - Safety profile in the patients with PRALIA administration changed to once every 3 months 2.Efficacy - Radiographic assessment of bone erosion progression	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026